Clinical Trial Update: A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase II multicenter randomized trial evaluating first-line chemotherapy with camrelizumab with or without radiotherapy for oligometastatic esophageal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• Camrelizumab (camrelizumab)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Esophageal Cancer | Phase 2 | Status: UNKNOWN